Home India Brazil Scraps Covaxin Emergency Use Application Amid Political Row: Report

Brazil Scraps Covaxin Emergency Use Application Amid Political Row: Report


Brazil Scraps Covaxin Emergency Use Application Amid Political Row: Report

Covaxin has been developed by Hyderabad-based Bharat Biotech.

Hyderabad:

After suspending the proposed clinical trials of Bharat Bioetch’s Covaxin, Brazil has now scrapped the Emergency Use Authorisation request made by the Indian firm for the vaccine.

The Brazilian health regulator’s decision comes after the vaccine maker informed the South American country about the termination of its pact with its partners in the country.

According to a statement issued by the National Health Surveillance Agency of Brazil, Anvisa, its Collegiate Board on Saturday unanimously decided “to close the process that dealt with the temporary authorization of emergency use, on an experimental basis, of the Covaxin vaccine”.

Earlier Anvisa had suspended the clinical studies of Bharat Biotech’s COVID-19 vaccine Covaxin in Brazil following the termination of the companys agreement with its partners there.

“The decision was taken after Anvisa was informed by the Indian company Bharat Biotech International Limited that the company Necessidade no longer has authorization to represent Bharat Biotech, manufacturer of the Covaxin vaccine, in Brazil,” Anvisa said.

Anvisa’s decision refers to the request for emergency use of Covaxin that had been filed by the Brazilian company Necessidade with Anvisa.

Bharat Biotech on July 23 said it terminated the MoU it entered with Precisa Medicamentos and Envixia Pharmaceuticals LL.C for its COVID-19 vaccine Covaxin for Brazilian market.

The termination of the MoU came after the deal with the Brazilian government for supply of 20 million doses of the Covaxin landed in controversy and attracted investigation by authorities in that country.

Following the graft allegations and subsequent inquiry by the authorities, the Brazilian government had earlier suspended Covaxin’s order temporarily.

Bharat Biotech will continue to work diligently with Anvisa, to complete the regulatory approval process for Covaxin, Bharat Biotech had said while announcing the termination of its pact with its Brazilian partners. 

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)



Source link

RELATED ARTICLES

Pradhan Mantri Digital Health Mission Nationwide Rollout On September 27

<!-- -->Digital Health Mission: The digital health ID will contain the health record of the citizen. (File)New Delhi: Prime Minister Narendra Modi will...

Yogi Adityanath Says Supporting Taliban Means Supporting Anti-India Acts

<!-- -->Yogi Adityanath said "every faith and community" are now free to celebrate their festivals. (File)Hapur (UP): Supporting the Taliban means supporting anti-India,...

In Madhya Pradesh, Woman Beaten Up, Chemical Poured In Her Eyes

<!-- -->Police have arrested two accused in connection with the incident.A 21-year-old woman in Madhya Pradesh's Panna district has suffered serious damage to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Horoscope Today: Astrological prediction for September 23

Daily horoscope: Are the stars lined up in your favour? Find out the astrological prediction for Aries, Leo, Virgo, Libra and other zodiac...

Pradhan Mantri Digital Health Mission Nationwide Rollout On September 27

<!-- -->Digital Health Mission: The digital health ID will contain the health record of the citizen. (File)New Delhi: Prime Minister Narendra Modi will...

Yogi Adityanath Says Supporting Taliban Means Supporting Anti-India Acts

<!-- -->Yogi Adityanath said "every faith and community" are now free to celebrate their festivals. (File)Hapur (UP): Supporting the Taliban means supporting anti-India,...

Quad Partnership On Track To Produce 1 Billion Covid Jabs In India, Says Joe Biden

<!-- -->Washington: The Quad partnership is on track to produce at least a billion vaccine doses in India by 2022, US President Joe...

Recent Comments